The Novacyt share price is flying. Should I buy the rebound?

The Novacyt share price is up by more than 15% today and the company has a number of new products. Roland Head asks if a recent dip is a buying opportunity.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

As I write, Covid-19 testing specialist Novacyt (LSE: NCYT) is Friday’s top riser on the London Stock Exchange. Novacyt’s share price is up by 17%, lifting the stock back above 400p. Investors seem to be buying back in to this popular stock, after a positive update on new Covid-19 testing products.

Today’s gains have helped to reverse the 40% slump seen two weeks ago, when Novacyt lost a key contract with the NHS. The stock is now broadly flat on one year ago. Is this an opportunity for me to buy this former winner at a bargain price? I’ve been taking a look.

Targeting new variants

The company’s new testing products seem to be designed to meet two needs. Firstly, there are new Lateral Flow Tests (LFT) to detect SARS-CoV-2 IgG antibodies. I assume these fast-acting tests are targeted at individuals and organisations who want to be able to test for immunity and get instant results. I’d expect this to be a growing market, at least for the next 12 months.

Novacyt’s scientists have also been developing new versions of its core PCR testing product, which detects Covid-19 infections. These tests still require lab processing for a result but are considered to be the most accurate type of test.

Among the new tests are products designed to detect new variants, such as the one originally identified in India.

All of these products sound promising to me, although I suspect they will all be quite short-lived — will we still be testing intensively for Covid-19 in 12 months’ time? Nobody knows.

Novacyt share price: not for me

Novacyt’s new products may have promise, but the firm has not revealed any new contracts to replace the lost NHS deal.

What worries me about this situation is that we’re four months into 2021, but Novacyt has just begun a legal dispute with its largest customer (the NHS) over revenue during the final three months of 2020. If this dispute goes against Novacyt, some of this money might never be received.

NHS sales generated 50% of its revenue during the first quarter of this year. But the company has failed to renew this contract and management does not expect the NHS to need any more PROmate PCR testing kits to meet demand in 2021.

Sales and profits are now expected to fall sharply this year. This makes me wonder how safe Novacyt’s cash pile will be. The company reported a cash balance of €101m on 31 December. But with sales falling short of expectations, I wonder if this cash will be needed to support product development costs.

Unfortunately, it may be some time until we find out more. Novacyt had planned to publish its 2020 results in April, but these have now been delayed to 29 June.

For me, there are just too many uncertainties here. I don’t have the information to work out whether Novacyt’s share price is really cheap. For this reason, I won’t be investing.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »